Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): A novel molecular probe

ChemMedChem

Volumn 9, Issue 8, 2014, Pages 1677-1682

  Gentry, Patrick R ^a   Kokubo, Masaya ^a   Bridges, Thomas M ^a   Cho, Hyekyung P ^a   Smith, Emery ^b   Chase, Peter ^b   Hodder, Peter S ^b   Utley, Thomas J ^a   Rajapakse, Anuruddha ^a   Byers, Frank ^a   Niswender, Colleen M ^a   Morrison, Ryan D ^a   Daniels, J Scott ^a   Wood, Michael R ^a   Conn, P Jeffrey ^a   Lindsley, Craig W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

acetylcholine; antagonists; molecular probes; muscarinic acetylcholine receptors; orthosteric ligands

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; METHYLSCOPOLAMINE; MULTIDRUG RESISTANCE PROTEIN; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG; VUO 488130; 5-((3-ACETYLPHENOXY)METHYL)-N-METHYL-N-(1-(PYRIDIN-2-YL)ETHYL)ISOXAZOLE-3-CARBOXAMIDE; ACETOPHENONE DERIVATIVE; ISOXAZOLE DERIVATIVE; MOLECULAR PROBE; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSFORMATION; ELECTROPHYSIOLOGY; ENANTIOMER; ENANTIOSELECTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; LIVER BLOOD FLOW; LIVER MICROSOME; MALE; MOLECULAR PROBE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; HALF LIFE TIME; METABOLISM; PHARMACOKINETICS;

ACETOPHENONES; ANIMALS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; ISOXAZOLES; MOLECULAR PROBES; MUSCARINIC ANTAGONISTS; PROTEIN BINDING; RATS; RECEPTOR, MUSCARINIC M5;

EID: 84905223141     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201402051     Document Type: Article

References (24)

1. J. Smythies, Int. Rev. Neurobiol. 2005, 64, 1-122.
2. J. Wess, R. M. Eglen, D. Gautam, Nat. Rev. Drug Discovery 2007, 6, 721-733.
3. C. J. Langmead, J. Watson, C. Reavill, Pharmacol. Ther. 2008, 117, 232-243.
4. D. Dencker, M. Thomsen, G. Wörtwein, G. Weikop, Y. Cui, J. Jeon, J. Wess, A. Fink-Jensen, ACS Chem. Neurosci. 2012, 3, 80-89.
5. M. P. Caulfield, N. J. M. Birdsall, Pharmacol. Rev. 1998, 50, 279-290.
6. D. M. Weiner, A. I. Levey, M. R. Brann, Proc. Natl. Acad. Sci. USA 1990, 87, 7050-7054.
7. R. P. Yasuda, W. Ciesla, L. R. Flores, S. J. Wall, M. Li, S. A. Satkus, J. S. Weisstein, B. V. Spagnola, B. B. Wolfe, Mol. Pharmacol. 1993, 43, 149-157.
8. A. S. Basile, I. Fedorova, A. Zapata, X. G. Liu, T. Shippenberg, A. Duttaroy, M. Yamada, J. Wess, Proc. Natl. Acad. Sci. USA 2002, 99, 11452-11457.
9. A. Fink-Jensen, I. Fedorova, G. Wörtwein, D. P. Woldbye, T. Rasmussen, M. Thomsen, T. G. Bolwig, K. M. Knitowski, D. L. McKinzie, M. Yamada, J. Wess, A. Basile, J. Neurosci. Res. 2003, 74, 91-96.
10. M. Thomsen, D. P. Woldbye, G. Wörtwein, A. Fink-Jensen, J. Wess, S. B. Caine, J. Neurosci. 2005, 25, 8141-8149.
11. J. S. Yeomans, J. Takeuchi, M. Baptista, D. D. Flynn, K. Lepik, J. Nobrega, J. Fulton, M. R. Ralph, J. Neurosci. 2000, 20, 8861-8867.
12. D. B. Lester, A. D. Miller, C. D. Blaha, Synapse 2010, 64, 216-223.
13. B. J. Melancon, C. R. Hopkins, M. R. Wood, K. A. Emmitte, C. M. Niswender, A. Christopoulos, P. J. Conn, C. W. Lindsley, J. Med. Chem. 2012, 55, 1445-1464.
14. P. J. Conn, C. Jones, C. W. Lindsley, Trends Pharmacol. Sci. 2009, 30, 148-156.
15. T. M. Bridges, J. E. Marlo, C. M. Niswender, J. K. Jones, S. B. Jadhav, P. R. Gentry, C. D. Weaver, P. J. Conn, C. W. Lindsley, J. Med. Chem. 2009, 52, 3445-3448.
16. T. M. Bridges, J. P. Kennedy, H. P. Cho, P. J. Conn, C. W. Lindsley, Bioorg. Med. Chem. Lett. 2010, 20, 558-562.
17. P. R. Gentry, T. M. Bridges, A. Lamsal, P. N. Vinson, E. Smith, P. Chase, P. S. Hodder, J. L. Engers, C. M. Niswender, J. S. Daniels, P. J. Conn, M. R. Wood, C. W. Lindsley, Bioorg. Med. Chem. Lett. 2013, 23, 2996-3000.
18. G. Zheng, A. M. Smith, X. Huang, K. L. Subramanian, K. B. Siripuarpu, A. Deaciuc, C.-G. Zhan, L. P. Dwoskin, J. Med. Chem. 2013, 56, 1693-1703.
19. P. R. Gentry, M. Kokubo, T. M. Bridges, N. R. Kett, J. M. Harp, H. P. Cho, E. Smith, P. Chase, P. S. Hodder, C. M. Niswender, S. J. Daniels, P. J. Conn, M. R. Wood, C. W. Lindsley, J. Med. Chem. 2013, 56, 9351-9355.
20. D. J. Sheffler, R. Williams, T. M. Bridges, L. M. Lewis, Z. Xiang, F. Zheng, A. S. Kane, N. E. Byum, S. Jadhav, M. M. Mock, F. Zheng, L. M. Lewis, C. K. Jones, C. M. Niswender, C. D. Weaver, P. J. Conn, C. W. Lindsley, P. J. Conn, Mol. Pharmacol. 2009, 76, 356-368.
21. ML381 is an MLPCN probe and freely available upon request from the Molecular Libraries Probe Centers Network (MLPCN); http://mli.nih.gov/mli/mlpcn/ .
22. For full details and supplemental structure-activity relationship data tables, see the Supporting Information.
23. For information on the Eurofins Lead Profiling Screen, see: http://www.eurfins.com.
24. C. J. Wenthur, C. M. Niswender, R. Morrison, J. S. Daniels, P. J. Conn, C. W. Lindsley, J. Med. Chem. 2013, 56, 5208-5212.